0001209191-23-006402.txt : 20230202 0001209191-23-006402.hdr.sgml : 20230202 20230202183747 ACCESSION NUMBER: 0001209191-23-006402 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230201 FILED AS OF DATE: 20230202 DATE AS OF CHANGE: 20230202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thye Dirk CENTRAL INDEX KEY: 0001638945 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 23582868 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Quince Therapeutics, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 901024039 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cortexyme, Inc. DATE OF NAME CHANGE: 20160104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-01 0 0001662774 Quince Therapeutics, Inc. QNCX 0001638945 Thye Dirk C/O CORTEXYME, INC. 601 GATEWAY BLVD, #1250 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 Chief Executive Officer Employee Stock Option (right to buy) 0.94 2023-02-01 4 A 0 600000 0.00 A 2033-01-31 Common Stock 600000 600000 D The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. /s/ Ted Monohon, Attorney-in-Fact for Dirk Thye 2023-02-02